- Home
- TRNR vs CMND Comparison
TRNR vs CMND Comparison
Compare TRNR & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRNR | CMND |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5M | 2.2M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRNR | CMND |
|---|---|---|
| Price | $1.46 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 13.3M | 54.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,380,000.00 | N/A |
| Revenue This Year | $245.67 | N/A |
| Revenue Next Year | $119.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 459.25 | N/A |
| 52 Week Low | $0.19 | $0.07 |
| 52 Week High | $8.20 | $3.25 |
Technical Indicators
Market Signals| Indicator | TRNR | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 57.29 | 32.47 |
| Support Level | $0.81 | $0.98 |
| Resistance Level | $1.62 | $1.07 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 56.21 | 10.31 |
Price Performance
Historical ComparisonAbout TRNR Interactive Strength Inc.
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue and personal training revenue.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.